A Kaul1, M Nagamani, B Nowicki. 1. Department of Obstetrics & Gynecology, University of Texas Medical Branch at Galveston 77555-1062, USA.
Abstract
PROBLEM: We investigated the level of decay accelerating factor (DAF) in the endometrium of luteal phase defect (LPD) patients, before and after treatment with progesterone. METHODS: Endometrial samples from fourteen normal-cycling controls and six samples from infertility patients with LPD before and four samples after progesterone treatment were stained by anti-DAF IgG using immunohistochemistry. RESULTS: Mean DAF OD in LPD patients was 15% compared to 60% in the control group. The mean DAF OD was 88% after treatment with progesterone. CONCLUSION: Results support interpretation that progesterone upregulates DAF while decreased progesterone may be associated with reduced expression of the DAF in LPD patients.
PROBLEM: We investigated the level of decay accelerating factor (DAF) in the endometrium of luteal phase defect (LPD) patients, before and after treatment with progesterone. METHODS: Endometrial samples from fourteen normal-cycling controls and six samples from infertilitypatients with LPD before and four samples after progesterone treatment were stained by anti-DAF IgG using immunohistochemistry. RESULTS: Mean DAF OD in LPD patients was 15% compared to 60% in the control group. The mean DAF OD was 88% after treatment with progesterone. CONCLUSION: Results support interpretation that progesterone upregulates DAF while decreased progesterone may be associated with reduced expression of the DAF in LPD patients.
Authors: P Goluszko; D Niesel; B Nowicki; R Selvarangan; S Nowicki; A Hart; E Pawelczyk; M Das; P Urvil; R Hasan Journal: Infect Immun Date: 2001-07 Impact factor: 3.441
Authors: Jacob W VanLandingham; Milos Cekic; Sarah Cutler; Stuart W Hoffman; Donald G Stein Journal: Neurosci Lett Date: 2007-08-25 Impact factor: 3.046